Amgen (AMGN) DIvidends Date & History

Key Takeaways

• Amgen pays a quarterly dividend of $2.52 per share, for an annual total of $10.08.
• Current dividend yield stands near 2.6%, slightly below the biotech industry average.
• The company has raised its dividend at an average annual rate of about 12% over the past decade.
• Payout ratio of approximately 67% indicates solid earnings coverage and sustainability.
• Dividend growth streak spans 13 consecutive years with no cuts.
• Free cash flow and earnings comfortably support ongoing payments.

Dividend Overview

Amgen Inc. (AMGN) follows a quarterly dividend payment schedule. The current quarterly dividend is $2.52 per share, resulting in an annualized payout of $10.08. This produces a dividend yield of roughly 2.6% based on recent share prices. Amgen is best characterized as a dividend growth stock with a modest yield. The policy emphasizes consistent increases supported by strong cash generation from its biopharmaceutical operations rather than pursuing the highest possible yield.

Dividend History and Growth

Amgen has maintained a long track record of dividend growth. Over the past ten years, the dividend has risen at an average annual rate of approximately 12%. The five-year growth rate stands near 8%. The company has increased its dividend for 13 consecutive years without reductions. Recent quarterly payments have stabilized at $2.52 after gradual step-ups from prior levels such as $2.38 and $2.25. This pattern reflects a deliberate strategy of sustainable growth aligned with expanding earnings and free cash flow.

Dividend Sustainability and Payout Ratio

The dividend appears sustainable given a payout ratio of about 67% of earnings. This level leaves ample retained earnings for reinvestment while providing comfortable coverage. Free cash flow also supports the payout at a similar ratio. Amgen maintains a strong balance sheet with manageable debt levels relative to its cash generation capacity. Expected earnings growth in the coming years should further bolster coverage and allow for continued dividend increases without straining finances.

Dividend Compared to Industry Peers

Amgen’s dividend yield of approximately 2.6% sits slightly below the biotech and pharmaceutical industry average near 2.8%. Peers in the sector often feature comparable or modestly higher yields, though many exhibit greater volatility in payouts. Amgen distinguishes itself through longer dividend growth consistency and lower payout ratios than some higher-yielding competitors, positioning it as a more conservative choice within the group.

AI Screener

Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps identify dividend stocks, income-focused investments, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening.

Is This Stock Attractive for Dividend Investors?

Amgen may appeal to dividend growth investors seeking moderate yields with a history of consistent increases. The quarterly payment schedule and payout ratio near 67% provide a balance of income and retained capital for business expansion. Long-term investors who value stability in the biotechnology sector could find the dividend profile suitable, particularly those prioritizing growth over maximum current yield. Conservative income investors might prefer higher-yielding alternatives, while those focused on capital appreciation alongside dividends may view the stock favorably. All assessments remain analytical and do not constitute investment recommendations.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations